New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 13, 2014
12:14 EDTHSP, MMSIMerit Medical recalls kits containing previously recalled Hospira product
Merit Medical Systems (MMSI) recalled Custom Procedural Trays/Kits manufactured from April 29, 2013 through August 20, 2013 due to the fact they contained Hospira (HSP) supplied 1% Lidocaine HCl, according to a posting to the FDA's website. The recall notice points out that Hospira previously announced on December 23, 2013 that it had initiated a voluntary nationwide recall to the user level for one lot of Lidocaine HCl Injection due to a reddish orange particulate on the inner surface and floating in the solution. Reference Link
News For MMSI;HSP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 20, 2015
09:52 EDTHSPAlliance for Health Reform holds a webcast on biosimilars
"Biosimilars in the U.S.: Current & Emerging Issues" provides essential background on the U.S. and international markets for reference biologics and biosimilars, outline current policy and regulatory issues, and describe implications for the future. Speakers include Chief Scientific Officer Ramachandra from Hospira, Executive Director Eich from Amgen on the briefing being held on May 20 at 12 pm. Webcast Link
May 14, 2015
12:29 EDTHSPPfizer receives 'second request' from FTC regarding potential Hospira merger
Subscribe for More Information
May 13, 2015
19:17 EDTHSPHospira and FDA detect security vulnerabilities in infusion pumps
Subscribe for More Information
13:43 EDTHSPHospira shareholders approve merger with Pfizer
Hospira (HSP) announced that Hospira shareholders voted in favor of the proposal to adopt the merger agreement with Pfizer (PFE) at a special meeting of stockholders held May 13 in Denver, Colorado. On February 5, Hospira and Pfizer announced they had entered into a merger agreement under which Pfizer will acquire Hospira for $90 per share in cash for a total enterprise value of approximately $17B. The merger is subject to customary closing conditions, one of which was approval of the merger by Hospira's shareholders. Additional closing conditions to be met include obtaining regulatory approvals in several jurisdictions. Hospira and Pfizer continue to expect the merger to close in the second half of 2015.
07:31 EDTMMSIHeart Rhythm Society to hold a conference
Heart Rhythm 2015 is being held in Boston on May 13-16.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use